The role of tocilizumab in the management of rheumatoid arthritis

Bibliography

• Gorter SL, Bijlsma JW, Cutolo M, Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69(6):1010-14
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Smolen JS, Landewe R, Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69(6):1004-9
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, Van Vollenhoven RF, Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69(6):976-86
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-75
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis research & therapy 2006;8(Suppl 2):S2
   PubMed Web of Science ®Google Scholar
• Andus T, Geiger T, Hirano T, Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS letters 1987;221(1):18-22
   PubMed Web of Science ®Google Scholar
• Gauldie J, Richards C, Harnish D, Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences of the United States of America 1987;84(20):7251-5
   PubMed Web of Science ®Google Scholar
• Kopf M, Baumann H, Freer G, Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368(6469):339-42
   PubMed Web of Science ®Google Scholar
• Hibi M, Murakami M, Saito M, Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990;63(6):1149-57
   PubMed Web of Science ®Google Scholar
• Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003;278(5):2903-12
   PubMed Web of Science ®Google Scholar
• Noma Y, Sideras P, Naito T, Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature 1986;319(6055):640-6
   PubMed Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takahashi N, Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90(24):11924-8
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer seminars in immunopathology 1998;20(1-2):247-59
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113(9):1271-6
   PubMed Web of Science ®Google Scholar
• Hirano T, Taga T, Nakano N, Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 1985;82(16):5490-4
   PubMed Web of Science ®Google Scholar
• Jourdan M, Bataille R, Seguin J, Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 1990;33(3):398-402
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74(4):1360-7
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Turner M, Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European journal of immunology 1988;18(11):1797-801
   PubMed Web of Science ®Google Scholar
• Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52(3):232-4
   PubMed Web of Science ®Google Scholar
• Straub RH, Muller-Ladner U, Lichtinger T, Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. British journal of rheumatology 1997;36(12):1298-303
   PubMedGoogle Scholar
• Sato K, Tsuchiya M, Saldanha J, Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993;53(4):851-6
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5(12):1731-40
   PubMed Web of Science ®Google Scholar
• Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50(7):754-66
   PubMed Web of Science ®Google Scholar
• Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol 2011;4(5):539-58
   PubMedGoogle Scholar
• Schmitt C, Kuhn B, Zhang X, Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 2011;89(5):735-40; Erratum appears in Clin Pharmacol Ther. 2011 Sep;90(3):479 Note: Dosage error in article text
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30(7):1426-35
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46(12):3143-50
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-29
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-97
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63(3):609-21
   PubMed Web of Science ®Google Scholar
• Genant HK, Jiang Y, Peterfy C, Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41(9):1583-90
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19(1):12-19
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(6):1761-9
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580-4
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66(9):1162-7
   PubMed Web of Science ®Google Scholar
• van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27(1):261-3
   PubMed Web of Science ®Google Scholar
• Yazici Y, Curtis JR, Ince A, Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012;71(2):198-205
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-80
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69(1):88-96
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-23
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Amano K, Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology 2011;50(10):1908-15
   PubMed Web of Science ®Google Scholar
• Dougados M, Huizinga T, Sheeran T, Tocilizumab (TCZ) plus methotrexate (MTX) does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results of the ACT-RAY study. Ann Rheum Dis 2011;70(Suppl 3):73
   Google Scholar
• Burmester GR, Feist E, Kellner H, Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70(5):755-9
   PubMed Web of Science ®Google Scholar
• Leffers HC, Ostergaard M, Glintborg B, Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70(7):1216-22
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Frey N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn 2012;39(1):5-16
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20(3):222-32
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010;69(7):1310-14
   PubMed Web of Science ®Google Scholar
• Schiff MH, Kremer JM, Jahreis A, Integrated safety in tocilizumab clinical trials. Arthritis Research and Therapy 2011;13:(5)R141:1-13
   Google Scholar
• Koike T, Harigai M, Inokuma S, Post-marketing surveillance program of tocilizumab for RA in Japan interim analyses of 3,881 patients. Arthritis Rheum 2010;62:399
   Google Scholar
• Fujiwara H, Nishimoto N, Hamano Y, Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 2009;19(1):64-8
   PubMed Web of Science ®Google Scholar
• Hirao M, Hashimoto J, Tsuboi H, Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 2009;68(5):654-7
   PubMed Web of Science ®Google Scholar
• Hiroshima R, Kawakami K, Iwamoto T, Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab. Mod Rheumatol 2011;21(1):109-11
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner H, Ruperte N, Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): 12-week data from the phase 3 TENDER trial. Clinical and Experimental Rheumatology 2011;29(2):371
   Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. The Lancet 2008;371(9617):998-1006
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Suzuki T, Tsuboi H, Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Internal Medicine 2007;46(11):771-4
   PubMed Web of Science ®Google Scholar
• Puechal X, DeBandt M, Berthelot JM, Tocilizumab in refractory adult Still's disease. Arthritis Care Res 2011;63(1):155-9
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62(2):542-52
   PubMed Web of Science ®Google Scholar
• Salvarani C, Magnani L, Catanoso M, Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012;51(1):151-6
   PubMed Web of Science ®Google Scholar
• Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011;30(11):1471-4
   PubMed Web of Science ®Google Scholar